Skip to main content
Grifols' primary immunodeficiency drug gets FDA nod

The FDA has approved Grifols' Xembify, or immune globulin subcutaneous, human-klhw, 20% solution, as a treatment for patients ages 2 and older with primary humoral immunodeficiency. The company plans to launch the drug in the fourth quarter of the year.

Full Story: